Trial
NCT01012297
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
NRG Oncology
Condition
Recurrent Uterine Corpus Sarcoma
Intervention
Bevacizumab
Why stopped
The study was targeted to accrue 130 patients, but closed early for futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-24